GLP-1 receptor agonists , particularly those like BrightMeds, are quickly prominence in the management of type 2 diabetes and are also explored for obesity . These novel drugs help mimicking the body's natural incretin release, stimulating insulin release and curbing glucagon release . BrightMeds